参考文献：

【1】 Li Q, Cao M, Lei L, Yang F, Li H, Yan X, He S, Zhang S, Teng Y, Xia C, Chen W. Burden of liver cancer: From epidemiology to prevention. Chin J Cancer Res. 2022 Dec 30;34(6):554-566.

【2】 Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359 (4):378-390.

【3】 KudoM,FinnRS,QinS,etal.Lenvatinibversus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:

a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163-1173.

【4】 Cappuyns, S., Corbett, V., Yarchoan, M., Finn, R. S., Llovet, J. M. (2023). Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.JAMA oncology.

【5】 Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018 Jul;19(7):940-952.

【6】 Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, Lin X, Chen X, Li E, Wang L, Chen C, Zou J. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020 Apr;21(4):571-580.

【7】 Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.

Richard S. Finn,Shukui Qin,Masatoshi Kudo,Tim Meyer,Frederic Boisserie,Songzi Li,Yaxi Chen,Gisoo Barnes,Ramil Abdrashitov,Andrew X. Zhu, andArndt Vogel Journal of Clinical Oncology202341:4_suppl,495-495

【8】 Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T. Y., ... Cheng, A. L. (2020). Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.New England Journal of Medicine,382(20), 1894-1905.

【9】 Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., ... Fan, J. (2021). Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2 3 study.The Lancet Oncology,22(7), 977-990.

【10】 Kelley, R. K., Rimassa, L., Cheng, A. L., Kaseb, A., Qin, S., Zhu, A. X., ... Yau, T. (2022). Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.The Lancet Oncology,23(8), 995-1008.

【11】 Finn, R. S., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., ... Llovet, J. (2022). LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC).Annals of Oncology,33, S1401.

【12】 Abou-Alfa, G. K., Lau, G., Kudo, M., Chan, S. L., Kelley, R. K., Furuse, J., ... Sangro, B. (2022). Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evidence, 1(8), EVIDoa2100070.

【13】 Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., ... Verset, G. (2023). Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.The Lancet.

【14】 中国临床肿瘤学会（CSCO）原发性肝癌诊疗指南（2022）

【15】 CADTH PCODR FINAL CLINICAL GUIDANCE REPORT：Clinical Report，ATEZOLIZUMAB (TECENTRIQ) (Hoffman La-Roche Limited)，Indication: In combination with bevacizumab, for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma who require systemic therapy.

【16】 Xiao B, Wang W, Zhang D. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. Onco Targets Ther. 2018 Aug 21;11:5059-5074.

【17】 Lee CL, et al. 2023 ASCO. Abs 4105.

【18】 中国医师协会肝癌专业委员会. 肝细胞癌分子靶向药物临床应用中国专家共识（2022版） [J] . 中华医学杂志, 2022, 102(34) : 2655-2668. DOI: 10.3760/cma.cn112137-20220623-01387.